| Date | Form | Description | Docs | XBRL | Pages |
| 06/24/96 | DEF 14A | Definitive proxy statements |
|
14 | |
| 06/19/96 | 10-C |
|
2 | ||
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
1 | |
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
2 | |
| 06/14/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 06/13/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 04/24/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 04/22/96 | 8-K | Current report filing |
|
4 | |
| 03/14/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
12 | |
| 01/29/96 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
44 |
Latest News & Events
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Read More...Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Read More...Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Read More...